Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 20/20 | 1.00 |
| ▸ | GABBR1 | Q9UBS5 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3123805 | 1.00 | GABBR2 (1.00) | GABBR2GABBR1 | |
| SCHEMBL3119363 | 1.00 | GABBR2 (1.00) | GABBR2GABBR1 | |
| SCHEMBL3119366 | 1.00 | GABBR2 (1.00) | GABBR2GABBR1 | |
| SCHEMBL3123795 | 1.00 | GABBR2 (1.00) | GABBR2GABBR1 | |
| SCHEMBL3108316 | 0.83 | GABBR2 (1.00) | GABBR2GABBR1 | |
| SCHEMBL3121907 | 0.79 | GABBR2 (1.00) | GABBR2GABBR1 | |
| SCHEMBL3111419 | 0.78 | GABBR2 (1.00) | GABBR2GABBR1 | |
| SCHEMBL3118358 | 0.78 | GABBR2 (1.00) | GABBR2GABBR1 | |
| SCHEMBL13268129 | 0.76 | GABBR2 (0.79) | GABBR2GABBR1 | |
| SCHEMBL26257034 | 0.74 | GABBR2 (0.63) | GABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186401-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2025-06-12 | — | — | US | claimed |
| US-20240390311-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-28 | — | — | US | claimed |
| EP-4405049-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS | The Regents of the University of California (US) | 2024-07-31 | — | — | EP | claimed |
| US-20230381125-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-30 | — | — | US | claimed |
| WO-2023178183-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND ALPHA-2 ADRENERGIC RECEPTORS FOR TREATMENT OF STRESS INDUCED DEPRESSION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-09-21 | — | — | WO | claimed |
| EP-4217002-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS | The Regents of the University of California (US) | 2023-08-02 | — | — | EP | claimed |
| WO-2023048781-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-30 | — | — | WO | claimed |
| WO-2022067044-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-31 | — | — | WO | claimed |
| US-20250186401-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2025-06-12 | — | — | US | disclosed |
| US-20240390311-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-28 | — | — | US | disclosed |
| EP-4405049-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS | The Regents of the University of California (US) | 2024-07-31 | — | — | EP | disclosed |
| EP-3865212-B1 | MICROFLUIDIC DEVICES AND METHODS FOR USE THEREOF IN MULTICELLULAR ASSAYS OF SECRETION | UNIV BRITISH COLUMBIA (CA) | 2024-03-13 | — | — | EP | disclosed |
| US-20230381125-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-30 | — | — | US | disclosed |
| WO-2023178183-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND ALPHA-2 ADRENERGIC RECEPTORS FOR TREATMENT OF STRESS INDUCED DEPRESSION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20220365072-A1 | Microfluidic Devices and Methods for Use Thereof in Multicellular Assays of Secretion | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-11-17 | — | — | US | disclosed |
| WO-2022067044-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-31 | — | — | WO | disclosed |
| US-20130252886-A1 | METHODS OF DELAYING AND TREATING DIABETES | MITOKINE BIOSCIENCE, LLC | 2013-09-26 | — | — | US | disclosed |
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | DPYD, NUDT1, HPRT1 | GABBR2 1611/4885GABBR1 1499/4885 |
| US-20250186401-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION | GABRB2, GABRB1, ADRB2 | GABBR2 13/4885GABBR1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.